Glucagon-like peptide-1 drugs appear to slow the speed at which alcohol enters the bloodstream, which diminishes its effects ...

MariTide is now progressing into phase 3 trials, with a focus on its long-term safety and efficacy. Amgen expects to apply ...

Marketing and manufacturing practices for compounded GLP-1RA drugs have come under FDA scrutiny, prompting policy changes.

GLP-1 weight-loss drugs like Ozempic and Zepbound might help protect people from health risks related to sleep apnea, ...

Glucagon-like peptide-1 (GLP-1) drugs mimic the GLP-1 hormone, which helps control insulin and blood sugar levels, decreases ...

On Oct. 30, Eli Lilly will announce third-quarter earnings results that could lift the stock, or pressure it further. Here ...

The approval was based on the SOUL trial, which evaluated oral semaglutide in adults 50 years and older with T2DM and established CV disease and/or chronic kidney disease.

Clinical Director of the National Institute of Drug Abuse Dr. Lorenzo Leggio, said GLP-1 drugs' effect on the brain can help ...

Eli Lilly and Company's strong Phase 3 diabetes drug results boost its GLP-1 franchise. Click for my updated look at LLY ...

Viking Therapeutics, Inc. ( NASDAQ: VKTX) Q3 2025 Earnings Call October 22, 2025 4:30 PM EDT Welcome to the Viking Therapeutics Third Quarter 2025 Financial Results Conference Call. [Operator ...

Instead of creating affordable products that improve health and lower costs, pharmaceutical companies focus on new drugs that will yield a healthy return on investment.